Spending More for Lung Cancer Treatment Did Not Substantially Increase Patients' Lives
Spending More for Lung Cancer Treatment Did Not Substantially Increase Patients' Lives
A new study finds that survival for elderly patients with lung cancer has changed little despite large increases in health-care expenditures for lung cancer treatment. The study by Harvard University, National Cancer Institute, and National Bureau of Economic Research researchers, to be published in the December 1, 2007, issue of Cancer, finds that average life expectancy rose by less than 1 month between 1983 and 1997, while costs rose by over $20,000 per patient.
Stable 5-Year Survival Rate
Lung cancer remains the top cause of cancer death in the United States, with an estimated 160,390 deaths expected to occur in 2007. The US spends more than $5
Articles in this issue
Ixabepilone Approved for the Treatment of Advanced Breast Cancer
Positive Results Announced From Pivotal Study of Bendamustine in Non-Hodgkin's Lymphoma
ASCO/ASH Release Updated Guidelines on Chemotherapy-Related Anemia Treatments
Spending More for Lung Cancer Treatment Did Not Substantially Increase Patients' Lives
FDA Approves Oral Topotecan for Relapsed Small-Cell Lung Cancer
Temsirolimus Improves Survival in Renal Cell Carcinoma Patients
Breast MRI: The Radiologist's Perspective
Continued Progress in Treatment Options for Multiple Myeloma: From Past to Present and Future
Dermatologic Issues in Cancer Patients: Review of a Review
The Three Most Common Chemotherapy-Related Skin Reactions
Anthracyclines Survive Targeted Therapy
Reducing the Burden of Cancer
Prostate Cancer, PSA, and Questions That Can Only Be Answered By Clinical Trials
Biochemical Failure in Prostate Cancer: Managing Patients with Limited Data
Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma
Recent Videos
